^
    Back
    Association details:
    Biomarker:DNMT3A mutation
    Cancer:Acute Myelogenous Leukemia
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor) +
    Xospata (gilteritinib) (Multi-tyrosine kinase inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    ASH 2021
    Title:

    Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

    Published date:
    11/04/2021
    Excerpt:
    CONTRADICTING EVIDENCE:...this multicenter, open-label, phase 1b trial (NCT03625505) to evaluate Ven + Gilt for R/R AML. Here, we report final response and survival endpoints, and molecular clearance among patients (pts) treated at the recommended phase two dose (RP2D)....Pts in the dose expansion cohort received Ven 400 mg + Gilt 120 mg (RP2D) daily in 28-day cycles, following Ven ramp-up....mCRc for DNMT3A+ and DMNT3Awt pts were 82.4% and 64.3%, respectively.
    DOI:
    10.1182/blood-2021-150743
    Trial ID:
    NCT03625505
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2020
    Title:

    1945 Venetoclax, FLT3 Inhibitor and Decitabine in FLT3mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial

    Published date:
    11/04/2020
    Excerpt:
    In 10 pts who were refractory to or relapsed after ‘triplet’ therapy, the most frequent mutations at screening were DNMT3A (4), IDH1/2 (4), and N/KRAS (3).
    Secondary therapy:
    decitabine